trial

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

NCTId NCT04421456
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 95 (actual)
Sponsored by Jazz Pharmaceuticals
Primary completion 2022-03-16
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
95 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2020-08-18
Primary completion
2022-03-16
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
GWP42003-P

Sponsors

Jazz PharmaceuticalsLead Sponsor

Sites

39 total
Bentonville, United StatesLittle Rock, United StatesGarden Grove, United StatesLemon Grove, United StatesOakland, United StatesPico Rivera, United StatesLargo, United StatesLauderhill, United StatesTampa, United StatesLincolnwood, United StatesShreveport, United StatesSt Louis, United States

Linked catalysts

1
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adj — primary completion2022-03-16

Facts & assertions

4 sourced
Enrollment
95
Phase
PHASE2
Primary Completion Date
2022-03-16
Status
TERMINATED
relationships
The graph out of here
drug
GWP42003-P
drug
lead_sponsor
Jazz Pharmaceuticals
company
indication
Schizophrenia
indication
Schizophrenia
indication